Dysfunction of GSK3β is involved in the pathogenesis of several psychoneuroses; therefore, GSK3β has been considered a therapeutic target for Alzheimer’s disease and bipolar disorder (Bhat et al., 2018; Ochoa, 2022). The gene discussed is GSK3B; the disease is neurotic disorder.